Literature DB >> 9287891

Safety evaluation and confidence intervals when the number of observed events is small or zero.

B D Jovanovic1, R J Zalenski.   

Abstract

A common objective in many clinical studies is to determine the safety of a diagnostic test or therapeutic intervention. In these evaluations, serious adverse effects are either rare or not encountered. In this setting, the estimation of the confidence interval (CI) for the unknown proportion of adverse events has special importance. When no adverse events are encountered, commonly used approximate methods for calculating CIs cannot be applied, and such information is not commonly reported. Furthermore, when only a few adverse events are encountered, the approximate methods for calculation of CIs can be applied, but are neither appropriate nor accurate. In both situations, CIs should be computed with the use of the exact binomial distribution. We discuss the need for such estimation and provide correct methods and rules of thumb for quick computations of accurate approximations of the 95% and 99.9% CIs when the observed number of adverse events is zero.

Mesh:

Year:  1997        PMID: 9287891     DOI: 10.1016/s0196-0644(97)70165-3

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  6 in total

1.  The role and interpretation of pilot studies in clinical research.

Authors:  Andrew C Leon; Lori L Davis; Helena C Kraemer
Journal:  J Psychiatr Res       Date:  2010-10-28       Impact factor: 4.791

2.  Copper intrauterine device placement 6-14 days after unprotected sex.

Authors:  Ivana Thompson; Jessica N Sanders; E Bimla Schwarz; Christy Boraas; David K Turok
Journal:  Contraception       Date:  2019-06-07       Impact factor: 3.375

3.  Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.

Authors:  Lin Fan; Yuanyuan Zhang; Peter Maguire; Dominic Muston; Matthew Monberg; Jagadeswara Rao Earla; Adela Mihai; Poonam Gulati
Journal:  J Mark Access Health Policy       Date:  2022-06-08

4.  Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).

Authors:  Robbin Itzler; Gary Koch; David O Matson; Leif Gothefors; Pierre Van Damme; Mark J Dinubile; Penny M Heaton
Journal:  BMC Pediatr       Date:  2010-06-11       Impact factor: 2.125

5.  Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.

Authors:  Cori Campbell; Monique I Andersson; M Azim Ansari; Olivia Moswela; Siraj A Misbah; Paul Klenerman; Philippa C Matthews
Journal:  Front Med (Lausanne)       Date:  2021-08-20

6.  Five-year risk of HIV diagnosis subsequent to 147 hospital-based indicator diseases: a Danish nationwide population-based cohort study.

Authors:  Lars Haukali Omland; Rebecca Legarth; Magnus Glindvad Ahlström; Henrik Toft Sørensen; Niels Obel
Journal:  Clin Epidemiol       Date:  2016-09-06       Impact factor: 4.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.